RUNX1 and acute myeloid leukemia: Considering this fundamental principle, translational researchers have created mouse models combining these different lesions, such as those expressing AML1-ETO (AE) inTet2+/– cells orAsxl2+/– cells or expressing FLT3-ITD inTet2+/– cells in order to better reflect and determine which treatments may work in which AML patient subtypes.